XML 58 R43.htm IDEA: XBRL DOCUMENT v3.24.1
Note 2 - Summary of Significant Accounting Policies (Details Textual)
$ in Thousands, € in Millions
12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Retained Earnings (Accumulated Deficit) $ (939,368)   $ (860,935)  
Working Capital 23,800      
Equity, Attributable to Parent 33,414   99,645 $ 169,246
Restricted Cash 1,600   1,100  
Debt Securities, Available-for-Sale, Realized Gain (Loss) 0   0  
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not to Sell before Recovery, Credit Loss, Previously Recorded, Expense (Reversal) 0   0  
Debt Securities, Available-for-Sale, Allowance for Credit Loss 0   0  
Accounts Receivable, Allowance for Credit Loss 1,600   1,600  
Property, Plant and Equipment, Including Purchased Software, Impairment Charges 400   1,400  
Proceeds From Employee Retention Tax Credit 600   700  
Business Combination, Contingent Consideration, Liability $ 2,220   $ 1,256  
Period Of Service Sale Arrangement (Year) 5 years 5 years    
Period of Service Sale Arrangement at Stated Service Price (Year) 4 years 4 years    
Lessor, Operating Lease, Payment to be Received $ 2,200      
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00% 0.00% 0.00%  
Number of Operating Segments 1 1    
Senhance Surgical Robotic System Acquisition[Member]        
Business Combination, Contingent Consideration, Liability $ 2,200      
Business Combination, Contingent Consideration, Liability, Related Milestone | €   € 15    
Minimum [Member]        
Lessee, Operating Lease, Term of Contract (Year) 1 year      
Lessee, Operating Lease, Renewal Term (Year) 1 year      
Minimum [Member] | Senhance Surgical Robotic System Acquisition[Member]        
Business Combination Contingent Consideration Arrangements Target Revenue | €   € 25    
Maximum [Member]        
Lessee, Operating Lease, Term of Contract (Year) 10 years      
Lessee, Operating Lease, Renewal Term (Year) 6 years      
Patents [Member]        
Finite-Lived Intangible Asset, Useful Life (Year) 10 years      
Developed Technology Rights [Member]        
Finite-Lived Intangible Asset, Useful Life (Year) 7 years      
Intellectual Property [Member]        
Impairment of Intangible Assets, Finite-Lived $ 0   $ 0  
Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Number of Major Customers 1 1 1  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member]        
Concentration Risk, Percentage 83.00% 83.00% 69.00%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member]        
Number of Major Customers 2 2 1  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]        
Concentration Risk, Percentage     47.00%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]        
Concentration Risk, Percentage 33.00% 33.00%    
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]        
Concentration Risk, Percentage 19.00% 19.00%    
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]        
Equity, Attributable to Parent $ 600   $ 1,900